NEZGLYAL

The European Commission has granted marketing authorization for NEZGLYAL (leriglitazone), making it the first pharmacological treatment approved for cerebral adrenoleukodystrophy, a rare and rapidly progressive neurodegenerative disease that primarily affects young boys. Until now, care options for cALD were limited mainly to stem cell transplantation in eligible patients. The approval is being highlighted as a significant milestone for families affected by the rare disease and for rare-disease drug development in Europe.